Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, Jardiance (empagliflozin).

Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes.

But new evidence suggests that Jardiance also reduces CV risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote